Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma

SALVINI, MARCO
First
;
BONELLO, FRANCESCA;BOCCADORO, Mario;LAROCCA, Alessandra
Last
2017

17
1
75
87
https://www.tandfonline.com/doi/abs/10.1080/14737140.2017.1266264?journalCode=iery20
https://doi.org/10.1080/14737140.2017.1266264
adverse events management; carfilzomib; immunomodulatory drugs; ixazomib; multiple myeloma; novel agents; pomalidomide; proteasome inhibitors; Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide; Oncology; Pharmacology (medical)
Salvini, Marco; Bonello, Francesca; Boccadoro, Mario; Larocca, Alessandra
File in questo prodotto:
File Dimensione Formato  
[Published Vsn.] Salvini et al - 2017 - Exp Rev Anticancer Th - Management of AEs.pdf

Accesso riservato

Descrizione: [Restricted access - Published Vsn.] Salvini M et al. Expert Rev Anticancer Ther . 2017 Jan;17(1):75-87. doi: 10.1080/14737140.2017.1266264. Epub 2016 Dec 9. © 2016 Informa UK Limited, trading as Taylor & Francis Group. Available at: https://www.tandfonline.com/doi/abs/10.1080/14737140.2017.1266264?journalCode=iery20 | https://doi.org/10.1080/14737140.2017.1266264
Tipo di file: PDF EDITORIALE
Dimensione 1.32 MB
Formato Adobe PDF
1.32 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
[Restricted access - Author Vsn] Salvini et al - 2017 - Expert Review of Anticancer Therapy - Management of Adverse Events - Post Print.pdf

Accesso aperto

Descrizione: [Restricted access - Author Vsn.] Salvini M et al. Expert Rev Anticancer Ther . 2017 Jan;17(1):75-87. doi: 10.1080/14737140.2017.1266264. Epub 2016 Dec 9. © 2016 Informa UK Limited, trading as Taylor & Francis Group. The published version is available at: https://www.tandfonline.com/doi/abs/10.1080/14737140.2017.1266264?journalCode=iery20 | https://doi.org/10.1080/14737140.2017.1266264
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 785.26 kB
Formato Adobe PDF
785.26 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1638135
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact